Angiogenesis is becoming a major target for antitumor therapies, and identifying new angiogenic factors and their specific inhibitors may provide new avenues for tumor management. Here we identify gastrin-releasing peptide (GRP) as a new angiogenic molecule that is secreted by tumors and acts directly upon GRP receptors in the endothelial cells. Addition of GRP increases endothelial cell migration and cord formation in vitro, and induces angiogenesis in an in vivo assay. We have recently identified a small molecule GRP blocker, compound 77427. This inhibitor significantly reduced endothelial cell cord formation in vitro and angiogenesis in vivo. Conversely, when applied to VEGF-induced angiogenesis, the small molecule did not have any effect, demonstrating its specificity. Furthermore, this GRP blocker was able to reduce lung tumor cell growth in vitro as demonstrated by MTT and clonogenic assays. When applied to a xenograft model with lung cancer cells, compound 77427 reduced tumor volume to undetectable sizes, although when the treatment was suspended, tumors began to grow again at normal rates. Our collective observations indicate that GRP is a new angiogenic peptide and that its inhibition offers an attractive tool to reduce tumor burden.
Introduction
Angiogenesis is becoming a major target for cancer therapy (Shimizu and Oku, 2004) . As the tumor mass develops, the cells in the middle of the tumor body get separated from blood vessels and thus from their nutrient and oxygen supply, reaching hypoxic conditions (defined as less than 2% O 2 ). In response to hypoxia, overexpression of a number of autocrine or paracrine tumor cell survival factors that regulate growth, angiogenesis, survival, and energy metabolism, occurs, usually mediated by the transcription factor HIF-1 (Lee et al., 2004; Shi and Fang, 2004) . Blocking these tumor-produced survival factors may provide a useful window of opportunity to suppress tumor growth (Heasley, 2001) .
We have recently found a new angiogenic factor, proadrenomedullin N-terminal 20 peptide (PAMP), which is able to induce angiogenesis in vivo at concentrations several orders of magnitude lower than traditional angiogenic factors such as vascular endothelium growth factor (VEGF) or adrenomedullin (AM) (Martı´nez et al., 2004b) . The receptor system through which PAMP exerts its actions has not been fully characterized; however, there are several reports indicating that PAMP may bind to the bombesin or gastrin-releasing peptide (GRP) receptors for some of its activities (Ohinata et al., 2000 (Ohinata et al., , 2001 . Thus, we hypothesized that if PAMP is an angiogenic factor that may be acting through GRP receptors, GRP itself may have an impact on angiogenesis. There are a few reports in the literature that further support this hypothesis, for example binding of GRP to rat brain microvascular endothelial cells has been reported (Vigne et al., 1995) , and exposure of prostate and lung cancer cells to GRP has been shown to stimulate secretion of proangiogenic factors (Levine et al., 2003; Moody et al., 2003a) .
In addition, GRP plays a role as an autocrine growth factor for cancer cells of different origins (Kim et al., 2002; Lango et al., 2002) , probably mediated through activation of the epidermal growth factor receptor and MAPK (Lui et al., 2003) . Inhibitors of GRP have shown promising antitumor effects in animal models (Kiaris et al., 1999; Moody et al., 2003a, b; Nock et al., 2005) and in the clinic (Chaudhry et al., 1999) . We have recently found a new class of GRP blockers that bind to the peptide rather than to the receptor (Martı´nez et al., 2004a) .
Here, we study whether GRP is a direct angiogenic factor for endothelial cells through in vitro and in vivo angiogenesis assays. Furthermore, we investigate the effects of the new nonpeptidic GRP blocker 77427 in inhibiting GRP-induced angiogenesis and tumor growth in vitro and in xenograft models. We conclude that GRP is indeed an angiogenic factor and that blocking the paracrine influence of tumor-secreted GRP on endothelial cells may provide new opportunities for managing tumor growth.
Results

Hypoxia does not induce GRP expression in tumor cells
Expression of many angiogenic factors is regulated by O 2 deprivation (Lee et al., 2004; Shi and Fang, 2004) . To study whether this is also the case for GRP, cell lines H209 and H1299 were subjected to hypoxia for different periods of time, and GRP mRNA levels were quantified by real time PCR (Figure 1a) . Expression of GRP in cells subjected to hypoxia did not change when compared to their normoxic counterparts (Figure 1a ). To ensure that the tumor cells had the ability to respond to the hypoxic insult, we analysed the contents for AM in the same samples. AM has been previously shown to respond to hypoxia rapidly (Garayoa et al., 2000) and, in fact, the levels of AM mRNA in cells exposed to low oxygen tension were much higher than those shown by normoxic cells (Figure 1b ).
Endothelial cells express GRP receptors
Binding of radiolabeled GRP to brain microvascular endothelial cells has been described in the rat (Vigne et al., 1995) . To make sure human endothelial cells express GRP receptors, we performed PCR analysis for the three human receptors, CGRP-R, NMBR, and BRS-3. Endothelial cells expressed low levels of GRP-R and high levels of NMBR, whereas no BRS-3 expression was detected (Figure 2 ). The tumor cell line H1299 presented expression of the three receptors. A fibroblast cell line transfected with human BRS-3 was used as a positive control (Figure 2 ).
GRP directly modifies endothelial cell behavior
GRP has been previously shown to induce expression of angiogenic factors in tumor cells, which in turn increase endothelial cell migration (Levine et al., 2003) , but a direct effect on endothelial cells has not been reported. To investigate if this happens, we studied the effect of exposing primary cultures of human endothelial cells to different concentrations of GRP on endothelial cell migration. As with other angiogenic factors (Martı´nez et al., 2004b) , GRP effects on migration produce a bellshaped curve with a maximum induction at 0.1 pM. At this concentration, endothelial cells migrate at a double rate than the control. The effect of GRP at this concentration was undistinguishable from the one elicited by 10 pM VEGF (Figure 3) .
We also investigated the effect of GRP in an endothelial cord formation assay. Endothelial cells were seeded over a matrigel substrate in the presence or absence of GRP. A dose-dependent increase in cord complexity was observed upon treatment with GRP. As an example, addition of 5 nM GRP resulted in a remarkable formation of tubular structures when compared with the untreated controls (Figure 4a,b) . That this reaction depended specifically on GRP was further demonstrated by adding 0.5 mM of the GRP blocker, 77427 (structure shown in Figure 4d ). This small molecule was found to interfere the binding between the monoclonal antibody 2A11 and synthetic GRP. Furthermore, 77427 reduced the GRP-induced intracellular increase in IP 3 by 79% in H1299 cells (Martı´nez et al., 2004a) . In the present experiment, the addition of the small molecule greatly reduced the complexity of the endothelial lattice (Figure 4c ). The number of knots per photographic field went from 371 (control) to 3775 for the addition of 5 nM GRP (Po0.001) and back to 1274 when GRP and 77427 were added together (compared to control P ¼ 0.02, compared to GRP alone P ¼ 0.003).
GRP acts as an angiogenic factor in vivo
To study the effects of GRP in an in vivo angiogenesis assay, we placed GRP alone or in combination with either the small molecule blocker, 77427, or the anti-GRP monoclonal antibody 2A11, in angioreactors that were analysed by DIVAA. GRP induced a robust angiogenic response by itself at 1 nM concentration (Po0.001 compared to untreated matrigel). This response was dose-dependently counteracted by both inhibitors, thus demonstrating the specificity of the response (Figure 5a ). To test the specificity of 77427, it was added to 1 nM VEGF. There was no statistically significant differences in angiogenic potential when comparing VEGF by itself with the mix VEGF þ 77427 (Figure 5b ), thus indicating that 77427 inhibits specifically GRP-induced angiogenesis.
The GRP blocker, 77427, reduces tumor growth in vitro GRP has been characterized as an autocrine growth factor for a number of tumors (Cuttitta et al., 1985; Kim et al., 2002; Lango et al., 2002; Moody et al., 2003b) and, before studying the effects of 77427 in xenograft tumor models, we needed to understand whether this small molecule is able to influence tumor growth as well as angiogenesis. Two different growth assays were performed with the lung cancer cell lines H1299 and H345; a regular MTT proliferation assay in which tumor cells attach to the plate (Figure 6a ), and a clonogenic assay which is substrate-independent and therefore more predictive of malignant behavior ( Figure 6b ). In both cases, a significant but modest dose-dependent reduction in the number of cells or colonies was observed, indicating that 77427 is able to reduce tumor cell number.
The GRP blocker, 77427, reduces xenograft tumor growth in vivo
Tumor growth depends on a number of different mechanisms that include tumor cell proliferation, rate of tumor cell demise through apoptosis, and available nutrient and O 2 supply, among others. Xenograft experiments have the advantage of taking all these variables into account and we decided to test the GRP blocker, 77427, in this setting. Cell line H1299 was grown in the flanks of 30 nude mice. These animals were divided in three groups that received intratumoral injections of either PBS (negative control) or two different concentrations of the inhibitor (Figure 7) . At 3 days after the first injection, a statistically significant difference was already observed between the treated and untreated groups (Po0.05), but this difference became much larger after the second injection (Po0.001). By day 8, tumors could not even be found in most of the treated mice. This difference remained while the treatment was applied, but when the treatment was suspended tumors in all animals began to grow as quickly as the untreated tumors. In animals receiving PBS alone (control group), there was also a slight retardation in growth while treatment was applied, and they experienced a faster growth rate after the injections were suspended. This may reflect some damage caused to the tumors by the needles, but still the difference between mice receiving PBS or compound 77427 was very significant.
Discussion
We have shown here that GRP expression is not regulated under hypoxic conditions, at least in lung cancer cell lines, but addition of GRP elicits endothelial cell migration and cord formation in vitro and augments angiogenesis in vivo. In addition, the GRP blocker 77427 inhibits GRP-induced cord formation, in vivo angiogenesis, and tumor cell growth. In a xenograft tumor model, 77427 dramatically reduced tumor size. Taken together, these results demonstrate that GRP is a direct angio- genic factor and that inhibition of the paracrine loop established between the tumor cell that secretes GRP and the endothelial cells may be useful for tumor therapy.
Although not all the gene products whose expression is upregulated under hypoxia are angiogenic factors, most proangiogenic molecules get elevated after oxygen deprivation (Scheurer et al., 2004) . There is some indirect evidence in the literature indicating a potential link between hypoxia and GRP. For example, the pulmonary neuroendocrine cells are an important source of GRP in the normal organism. These cells function as hypoxia-sensitive chemoreceptors and in situations of pathologic chronic hypoxia, as found in chronic bronchitis, emphysema, and several smokingassociated lung disorders, there is a marked increase in the number of GRP-producing endocrine cells (Johnson and Georgieff, 1989; Sissons and Gosney, 1990; Schuller et al., 2000) . Our experimental data indicate that GRP expression is not regulated by hypoxia in lung cancer cells, thus defining GRP as a member of the small but growing class of angiogenic factors whose expression is not part of the tumor survival response to low oxygen tension environments (Michiels et al., 1998; Safronova et al., 2003; Lockwood et al., 2004) . On the other hand, stimuli that modulate GRP expression (Whitley et al., 2000; Hayashi et al., 2001 ) may influence the angiogenic process, indirectly through GRP upregulation.
Binding of radiolabeled GRP to rat microvascular endothelial cells has been described and the pharmacological profile of this binding indicated the existence of a neuromedin-B-preferring receptor (Vigne et al., 1995) . Our PCR profiling is in agreement with this observation since NMBR was the receptor with higher expression. Our observations and previous studies suggest the existence of a paracrine mechanism by which GRP is secreted by the tumor cells (Kiaris et al., 1999; Lango et al., 2002; Kim et al., 2002; Moody et al., 2003b) , diffuses through the extracellular milieu and binds to specific receptors in the endothelial cell surface. The activated endothelial cells have more ability to migrate and form primitive capillaries, thus initiating angiogenic sprouting. Another characteristic of the angiogenic process is the secretion of proteases that degrade components of the extracellular matrix to allow cell migration. GRP has been shown to activate promatrix metalloproteinase-9 through a mechanism involving beta1 integrin (Festuccia et al., 2002) , thus contributing to matrix remodeling.
Interestingly, a previous report using human umbilical endothelial cells (HUVECs) did not find any angiogenic change in either proliferation, migration, or tube formation, upon treatment with bombesin or neurotensin (Busby et al., 2003) . Many differences have been reported between endothelial cells derived from the macrovasculature and the microvasculature (Groger et al., 2000; Salcedo et al., 2000; Otto et al., 2001 ) and angiogenic potential in response to GRP seems to be another one of them. Since new blood vessels sprout from the microvasculature, the lack of angiogenic response in HUVECs is not surprising.
We have also characterized a small molecule GRP blocker that is able to reduce tumor cell proliferation and endothelial cell cord formation in vitro. The same molecule was also efficient in counteracting GRPinduced but not VEGF-induced angiogenesis in an in vivo model and to reduce tumor growth in a xenograft study. The impressive reduction in tumor growth in vivo is in sharp contrast with the modest reduction in tumor cell proliferation in vitro as studied by either MTT or clonogenic assays. This difference suggests that the predominant effect of GRP in tumor progression may be induction of angiogenesis rather than acting as a tumor growth factor. This view is also supported by the growth of the xenografted tumors once the inhibitory pressure was lifted. This, first, demonstrates that although the tumors all but disappeared, the inhibitor was not cytotoxic since the tumor cells were able to function normally in the absence of the drug. Secondly, this behavior has been previously described for other antiangiogenic drugs (Soffer et al., 2001) , stressing the need to develop combination therapies including a cytotoxic agent and an antiangiogenic substance (Los and Voest, 2001; Wachsberger et al., 2003) . Other small molecules that inhibit GRP activity have been shown to be efficient in reducing tumor growth in vivo (Shirahige et al., 1994; Moody et al., 1996b; Damge and Hajri, 1998) . In view of our results, it would be interesting to investigate whether angiogenesis blockade is also part of their mechanism of action.
In summary, GRP is a tumor-produced factor that acts as a direct angiogenic molecule upon binding to receptors present in the endothelial cells. Specific inhibitors of GRP reduce both tumor cell growth and angiogenesis, indicating their potential use as a clinical tool in the management of tumor growth, preferentially in combination with cytotoxic agents.
Materials and methods
Reagents
Synthetic human GRP was purchased from Bachem (Torrance, CA, USA). Recombinant human VEGF was obtained from R&D Systems (Minneapolis, MN, USA) . The nonpeptide GRP antagonist, 77427, was supplied by the Developmental Therapeutics Program (NCI, NIH). The blocking monoclonal antibody against GRP, 2A11, was produced in house and has been previously characterized (Cuttitta et al., 1985) .
Cells and hypoxia treatment
Human dermal microvascular endothelial cells (DMEC) were purchased from Cell Applications, Inc. (San Diego, CA, USA) and maintained in the medium supplied with the cells. Lung cancer cell lines H209, H345, and H1299 were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI 1640 supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). These cell lines express different levels of GRP and its receptors (Moody et al., 1996a) . In addition, BALB 3T3 fibroblasts overexpressing the human GRP receptor BRS-3 (Mantey et al., 2001) were used as a positive control. For hypoxia experiments, equal number of tumor cells were seeded in tissue culture flasks, some flasks were subjected to reduced oxygen tension (1% O 2 , 5% CO 2 , 94% N 2 ) in a hypoxia chamber as described (Garayoa et al., 2000) , while partner control flasks were kept in normoxia (21% O 2 , 5% CO 2 , 74% N 2 ) for the indicated periods of time.
Quantification of gene expression
Total RNA was extracted using the RNeasy Mini Kit from Qiagen and reverse transcribed using the SuperScript FirstStrand Synthesis system (Invitrogen). Quantification of gene expression was performed by real-time PCR as described (Martı´nez et al., 2004b) . The PCR reaction was run in an Opticon cycler (MJ Research, Waltham, MA, USA) using Sybr Green PCR master mix (Applied Biosystems, Foster City, CA, USA). Thermocycling was performed in a final volume of 25 ml containing 2 ml of cDNA (1 : 10 dilution) and 400 nM of primers (see below). All targets were amplified in triplicates in the same run as the house-keeping gene, using the following cycle scheme: after initial denaturation of the samples at 951C for 2 min, 46 cycles of 951C for 30 s, 601C for 30 s, and 721C for 30 s were performed. Fluorescence was measured in every cycle and mRNA levels were normalized by the 18S RNA values in all samples. A melting curve was run after PCR by increasing the temperature from 60 to 961C (0.51C increments). A single peak was obtained for all amplicons, thus confirming the specificity of the reaction. Primers were as follows:
GRP forward: GGGGCACTTAATGGGGAAAAAG GRP reverse: GCAGCTTCTTCCCACCTGATG AM forward: ACA TGA AGG GTG CCT CTC GAA AM reverse: AGG CCC TGG AAG TTG TTC ATG 18 S forward: ATG CTC TTA GCT GAG TGT CCC G 18 S reverse: ATT CCT AGC TGC GGT ATC CAG G In addition, regular PCR reactions were performed to identify GRP receptors in human microvascular endothelial cells. Primers for the 3 GRP receptors were: GRP-R forward: GATACAAAGCCATTGTCCGGC GRP-R reverse: AAGGTCTGGTTGGTGCTTTCC NMB-R forward: CGACAGGTACAGAGCCATCGTT NMB-R reverse: GATGCGAGCCACTTCTGAAAAC BRS-3 forward: GCTCTGTGGTTTCTAACG BRS-3 reverse: CTGCCTTGTATCTGTCAGC
Migration assay
Cell motility was measured as described (Martı´nez et al., 2004b) . Test peptides were placed at various concentrations at the bottom of a ChemoTx chamber (NeuroProbe Inc., Gaithesburg, MD, USA). The intermediate membrane was coated with 10 mg/ml fibronectin, and in the upper chamber 5.0 Â 10 5 human DMEC were added per well. After a 4-h incubation at 371C, the membrane was fixed and stained (Protocol Hema3, Biochemical Sciences Inc.) . The cells trapped in the porous membrane were photographed through a Â 25 microscope objective and the number of cells per photographic field was counted.
Cord formation assay
Human DMECs were seeded at 2.0 Â 10 5 cells per well over a solid layer of matrigel covering the bottom of a 24-well plate in the presence or absence of the test peptides, as described (Martı´nez et al., 2004b) . After an overnight incubation, the tubular structures were photographed and the number of knots per photographic field was counted as a measure of lattice complexity.
Directed in vivo angiogenesis assay (DIVAA)
Analysis and quantitation of angiogenesis was carried out using DIVAA as previously described (Martı´nez et al., 2002 (Martı´nez et al., , 2004b . Briefly, 10 mm long surgical-grade silicone tubes with only one end open (angioreactors) were filled with 20 ml of matrigel mixed with GRP or VEGF, either alone or in combination with inhibitors (77427 or the monoclonal antibody) at the indicated concentrations. After the matrigel solidified, the angioreactors were implanted into the dorsal flanks of athymic nude mice (NCI colony). After 11 days, the mice were injected i.v. with 25 mg/ml FITC-dextran (100 ml/ mouse, Sigma) 20 min before removing angioreactors. Quantitation of neovascularization in the angioreactors was determined as the amount of fluorescence trapped in the implants and was measured in an HP Spectrophotometer (Perkin Elmer). This protocol was approved by the internal NIH animal committee.
Proliferation assay
Tumor cells (H345 and H1299) were seeded in 96-well plates at a density of 2.0 Â 10 5 cells per well in serum-free medium (RPMI 1640) containing different concentrations of the small molecule inhibitor or the same amount of the vehicle (DMSO). After 5 days in culture, the number of viable cells per well was estimated by the MTT assay (Promega, Madison, WI, USA) as reported (Martı´nez et al., 2004b) . Results are represented as percentage cell number as compared to the untreated control.
Clonogenic assay
The effects of compound 77427 on the growth of the tumor cells was investigated using a clonogenic assay as described (Moody et al., 2004) . The base layer consisted of 3 ml of 0.5% agarose in TIS medium (RPMI 1640 containing 10 mg/ml transferrin, 5 mg/ml insulin, and 30 nM sodium selenite) containing 5% fetal bovine serum in six-well plates. The top layer consisted of 3 ml of TIS in 0.3% agarose, 5 Â 10 4 tumor cells, and the proper concentration of 77427. Triplicate wells were plated and after 2 weeks, 1 ml of 0.1% p-iodonitrotetrazolium violet was added for 16 h at 371C, and plates were screened for colony formation. Only colonies larger than 50 mm in diameter were counted.
Xenograft experiment
In total, 30 female athymic nude mice from the NIH colony in Frederick (MD) were injected subcutaneously with 1.0 Â 10 7 H1299 cells/mouse. After 2 weeks, all the mice had developed palpable tumors under the skin and at this time they were randomly divided in three groups. Three times a week, each individual tumor was measured (length, height, thickness) and every mouse received an intratumoral injection, according to their group. Group 1 (control) received 100 ml PBS; group 2 received 100 ml 0.5 mM of compound 77427 in PBS; and group 3 received 100 ml 5.0 mM of compound 77427 in PBS. When the tumor burden became large (greater than 2000 mm 3 ), the mice were killed. This schedule was chosen based on previous antiangiogenic treatments in xenograft studies (Martı´nez et al., 2004b) . As with the other animal experiments, this study was carried out under an NIH-approved protocol.
Statistical analysis
When appropriated, data were compared by two-tailed Student's t-test. P-values lower than 0.05 were considered statistically significant.
